TY - JOUR
T1 - S100A8 and S100A9 Are Important for Postnatal Development of Gut Microbiota and Immune System in Mice and Infants
AU - Willers, Maike
AU - Ulas, Thomas
AU - Völlger, Lena
AU - Vogl, Thomas
AU - Heinemann, Anna S.
AU - Pirr, Sabine
AU - Pagel, Julia
AU - Fehlhaber, Beate
AU - Halle, Olga
AU - Schöning, Jennifer
AU - Schreek, Sabine
AU - Löber, Ulrike
AU - Essex, Morgan
AU - Hombach, Peter
AU - Graspeuntner, Simon
AU - Basic, Marijana
AU - Bleich, Andre
AU - Cloppenborg-Schmidt, Katja
AU - Künzel, Sven
AU - Jonigk, Danny
AU - Rupp, Jan
AU - Hansen, Gesine
AU - Förster, Reinhold
AU - Baines, John F.
AU - Härtel, Christoph
AU - Schultze, Joachim L.
AU - Forslund, Sofia K.
AU - Roth, Johannes
AU - Viemann, Dorothee
N1 - Funding Information:
Funding This work was supported by grants to Dorothee Viemann from the Volkswagen Foundation (Az 90 005), the Appenrodt Foundation and the Deutsche Forschungsgemeinschaft (DFG) (VI 538/6-1), grants by the DFG to Johannes Roth and Thomas Vogl (CRC1009, B08 and B09) and to Dorothee Viemann, Gesine Hansen, and Reinhold F?rster by the DFG under Germany`s Excellence Strategy ? EXC 2155 ?RESIST? ? Project ID 39087428. John F. Baines was funded by the DFG under Germany`s Excellence Strategy ? EXC 22167-390884018 and CRC1182. Christoph H?rtel was funded by the Federal Ministry of Education and Research (BMBF; PRIMAL clinical study, No. 01GL1746A), the University of L?beck and the L?beck-Hilfe f?r krebskranke Kinder e.V. Joachim L. Schultze is a member of the Excellence Cluster ImmunoSensation.We thank Christiane Ritter for technical assistance and Yvonne Lueder for advice on image analysis. We acknowledge the assistance of the Cell Sorting Core Facility of the Hannover Medical School supported in part by Braukmann-Wittenberg-Herz-Foundation and the German Research Foundation. We are grateful to all parents contributing to this study. Maike Willers, PhD (Conceptualization: Equal; Data curation: Lead; Formal analysis:, Equal; Investigation: Lead; Methodology: Lead; Writing ? original draft: Lead), Thomas Ulas, PhD (Data curation: Lead; Formal analysis: Lead; Software: Equal;, Writing ? original draft: Equal). Lena V?llger, PhD (Data curation: Equal; Formal analysis: Equal; Investigation: Lead; Methodology: Lead; Supervision: Supporting; Writing ? original draft: Supporting). Thomas Vogl, PhD (Funding acquisition: Supporting; Investigation: Supporting; Methodology: Supporting; Validation: Supporting; Writing ? original draft: Supporting). Anna S. Heinemann, N/A (Conceptualization: Supporting; Data curation: Supporting; Investigation: Supporting; Methodology: Supporting). Sabine Pirr, MD (Conceptualization: Equal; Funding acquisition: Supporting; Investigation: Equal; Project administration: Supporting; Supervision: Equal; Writing ? original draft: Supporting). Julia Pagel, MD (Data curation: Supporting; Investigation: Supporting). Beate Fehlhaber, PhD (Data curation: Supporting; Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting). Olga Halle, Ph.D. (Conceptualization: Supporting; Formal analysis: Equal; Investigation: Supporting; Methodology: Lead). Jennifer Sch?ning, N/A (Formal analysis: Equal; Methodology: Equal; Supervision: Supporting; Visualization: Lead). Sabine Schreek, N/A (Formal analysis: Equal; Investigation: Equal; Methodology: Equal). Ulrike L?ber, PhD (Formal analysis: Supporting). Morgan Essex, PhD (Formal analysis: Supporting). Peter Hombach, N/A (Data curation: Supporting; Formal analysis: Supporting;, Methodology: Supporting; Software: Supporting). Simon Graspeuntner, PhD (Data curation: Supporting; Formal analysis: Supporting; Software: Supporting). Marijana Basic, PhD (Investigation: Supporting; Methodology: Supporting). Andre Bleich, PhD (Methodology: Supporting; Resources: Supporting). Katja Cloppenborg-Schmidt, N/A (Data curation: Supporting; Formal analysis: Supporting; Investigation: Supporting; Methodology: Equal). Sven K?nzel, PhD (Data curation: Equal; Methodology: Equal). Danny Jonigk, MD (Data curation: Supporting; Investigation: Supporting; Methodology: Supporting). Jan Rupp, MD, PhD (Resources: Supporting; Supervision: Supporting). Gesine Hansen, MD, PhD (Resources: Supporting). Reinhold F?rster, PhD (Resources: Supporting). John F. Baines, PhD (Conceptualization: Supporting; Methodology: Supporting; Resources: Supporting). Christoph H?rtel, MD, PhD (Data curation: Supporting; Formal analysis: Supporting;, Writing ? review & editing: Supporting). Joachim L. Schultze, PhD, MD (Resources: Supporting). Sofia K. Forslund, PhD (Formal analysis: Lead; Methodology: Supporting;, Supervision: Supporting; Validation: Lead; Writing ? review & editing: Equal). Johannes Roth, MD, PhD (Conceptualization: Supporting; Data curation: Supporting; Formal analysis: Supporting; Funding acquisition: Supporting; Resources: Supporting; Writing ? review & editing: Supporting). Dorothee Viemann, PhD, MD (Conceptualization: Lead; Funding acquisition: Lead; Investigation: Equal; Project administration: Lead; Supervision: Lead; Writing ? review & editing: Lead).
Publisher Copyright:
© 2020 The Authors
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Background & Aims: After birth, the immune system matures via interactions with microbes in the gut. The S100 calcium binding proteins S100A8 and S100A9, and their extracellular complex form, S100A8–A9, are found in high amounts in human breast milk. We studied levels of S100A8–A9 in fecal samples (also called fecal calprotectin) from newborns and during infancy, and their effects on development of the intestinal microbiota and mucosal immune system. Methods: We collected stool samples (n = 517) from full-term (n = 72) and preterm infants (n = 49) at different timepoints over the first year of life (days 1, 3, 10, 30, 90, 180, and 360). We measured levels of S100A8–A9 by enzyme-linked immunosorbent assay and analyzed fecal microbiomes by 16S sRNA gene sequencing. We also obtained small and large intestine biopsies from 8 adults and 10 newborn infants without inflammatory bowel diseases (controls) and 8 infants with necrotizing enterocolitis and measured levels of S100A8 by immunofluorescence microscopy. Children were followed for 2.5 years and anthropometric data and medical information on infections were collected. We performed studies with newborn C57BL/6J wild-type and S100a9–/– mice (which also lack S100A8). Some mice were fed or given intraperitoneal injections of S100A8 or subcutaneous injections of Staphylococcus aureus. Blood and intestine, mesenterial and celiac lymph nodes were collected; cells and cytokines were measured by flow cytometry and studied in cell culture assays. Colon contents from mice were analyzed by culture-based microbiology assays. Results: Loss of S100A8 and S100A9 in mice altered the phenotypes of colonic lamina propria macrophages, compared with wild-type mice. Intestinal tissues from neonatal S100-knockout mice had reduced levels of CX3CR1 protein, and Il10 and Tgfb1 mRNAs, compared with wild-type mice, and fewer T-regulatory cells. S100-knockout mice weighed 21% more than wild-type mice at age 8 weeks and a higher proportion developed fatal sepsis during the neonatal period. S100-knockout mice had alterations in their fecal microbiomes, with higher abundance of Enterobacteriaceae. Feeding mice S100 at birth prevented the expansion of Enterobacteriaceae, increased numbers of T-regulatory cells and levels of CX3CR1 protein and Il10 mRNA in intestine tissues, and reduced body weight and death from neonatal sepsis. Fecal samples from term infants, but not preterm infants, had significantly higher levels of S100A8–A9 during the first 3 months of life than fecal samples from adults; levels decreased to adult levels after weaning. Fecal samples from infants born by cesarean delivery had lower levels of S100A8–A9 than from infants born by vaginal delivery. S100 proteins were expressed by lamina propria macrophages in intestinal tissues from infants, at higher levels than in intestinal tissues from adults. High fecal levels of S100 proteins, from 30 days to 1 year of age, were associated with higher abundance of Actinobacteria and Bifidobacteriaceae, and lower abundance of Gammaproteobacteria—particularly opportunistic Enterobacteriaceae. A low level of S100 proteins in infants’ fecal samples associated with development of sepsis and obesity by age 2 years. Conclusion: S100A8 and S100A9 regulate development of the intestinal microbiota and immune system in neonates. Nutritional supplementation with these proteins might aide in development of preterm infants and prevent microbiota-associated disorders in later years.
AB - Background & Aims: After birth, the immune system matures via interactions with microbes in the gut. The S100 calcium binding proteins S100A8 and S100A9, and their extracellular complex form, S100A8–A9, are found in high amounts in human breast milk. We studied levels of S100A8–A9 in fecal samples (also called fecal calprotectin) from newborns and during infancy, and their effects on development of the intestinal microbiota and mucosal immune system. Methods: We collected stool samples (n = 517) from full-term (n = 72) and preterm infants (n = 49) at different timepoints over the first year of life (days 1, 3, 10, 30, 90, 180, and 360). We measured levels of S100A8–A9 by enzyme-linked immunosorbent assay and analyzed fecal microbiomes by 16S sRNA gene sequencing. We also obtained small and large intestine biopsies from 8 adults and 10 newborn infants without inflammatory bowel diseases (controls) and 8 infants with necrotizing enterocolitis and measured levels of S100A8 by immunofluorescence microscopy. Children were followed for 2.5 years and anthropometric data and medical information on infections were collected. We performed studies with newborn C57BL/6J wild-type and S100a9–/– mice (which also lack S100A8). Some mice were fed or given intraperitoneal injections of S100A8 or subcutaneous injections of Staphylococcus aureus. Blood and intestine, mesenterial and celiac lymph nodes were collected; cells and cytokines were measured by flow cytometry and studied in cell culture assays. Colon contents from mice were analyzed by culture-based microbiology assays. Results: Loss of S100A8 and S100A9 in mice altered the phenotypes of colonic lamina propria macrophages, compared with wild-type mice. Intestinal tissues from neonatal S100-knockout mice had reduced levels of CX3CR1 protein, and Il10 and Tgfb1 mRNAs, compared with wild-type mice, and fewer T-regulatory cells. S100-knockout mice weighed 21% more than wild-type mice at age 8 weeks and a higher proportion developed fatal sepsis during the neonatal period. S100-knockout mice had alterations in their fecal microbiomes, with higher abundance of Enterobacteriaceae. Feeding mice S100 at birth prevented the expansion of Enterobacteriaceae, increased numbers of T-regulatory cells and levels of CX3CR1 protein and Il10 mRNA in intestine tissues, and reduced body weight and death from neonatal sepsis. Fecal samples from term infants, but not preterm infants, had significantly higher levels of S100A8–A9 during the first 3 months of life than fecal samples from adults; levels decreased to adult levels after weaning. Fecal samples from infants born by cesarean delivery had lower levels of S100A8–A9 than from infants born by vaginal delivery. S100 proteins were expressed by lamina propria macrophages in intestinal tissues from infants, at higher levels than in intestinal tissues from adults. High fecal levels of S100 proteins, from 30 days to 1 year of age, were associated with higher abundance of Actinobacteria and Bifidobacteriaceae, and lower abundance of Gammaproteobacteria—particularly opportunistic Enterobacteriaceae. A low level of S100 proteins in infants’ fecal samples associated with development of sepsis and obesity by age 2 years. Conclusion: S100A8 and S100A9 regulate development of the intestinal microbiota and immune system in neonates. Nutritional supplementation with these proteins might aide in development of preterm infants and prevent microbiota-associated disorders in later years.
UR - http://www.scopus.com/inward/record.url?scp=85093819380&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2020.08.019
DO - 10.1053/j.gastro.2020.08.019
M3 - Journal articles
C2 - 32805279
AN - SCOPUS:85093819380
SN - 0016-5085
VL - 159
SP - 2130-2145.e5
JO - Gastroenterology
JF - Gastroenterology
IS - 6
ER -